ERBB2 and breast carcinoma: In clinical applications, trastuzumab deruxtecan (DXd) and sacituzumab govitecan (SN-38) have demonstrated improvements in progression-free and overall survival in HER2-low breast cancer and metastatic triple-negative breast cancer, respectively, thereby validating the clinical utility of the topoisomerase I inhibitor class [93,94].